A Phase 1b/2 Open-Label Study of Amivantamab Monotherapy, Amivantamab in Addition to Paclitaxel and Amivantamab in Addition to Pembrolizumab, in Participants with Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Status

Active (Non-Recruiting)

Disease

Head and Neck Squamous Cell Carcinoma

Treament Agent

Amivantamab + Paclitaxel

Study Phase

1b/ 2

Physician Name(s)

Dr Malwinder Singh Sandhu

Dr John Low Seng Hooi

Datuk Dr Lam Kai Seng

Description

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

Cancer Type

Head and Neck Cancer

I would like to be a part of tomorrow's breakthrough

Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.

In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.

If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you: